Meloxicam

Meloxicam is a synthetic NSAID belonging to the enolic acid, or oxicam, family, chemically related to piroxicam. It is used to treat the pain and inflammation of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and juvenile arthritis, and it is taken by mouth as tablets or suspension, given rectally, or, in newer formulations, by injection ^[2]. It is a very commonly prescribed drug; in the United States it has ranked among the most frequently dispensed medications ^[2].

Meloxicam's defining pharmacological feature is its relative selectivity for cyclooxygenase-2. NSAIDs relieve pain and inflammation by blocking cyclooxygenase enzymes, which make prostaglandins; the COX-2 form is switched on at sites of inflammation, whereas COX-1 maintains protective functions such as the stomach lining and normal platelet activity ^[1]. By inhibiting COX-2 more than COX-1, especially at lower doses, meloxicam aims to keep anti-inflammatory efficacy while reducing the gastric injury linked to COX-1 blockade ^[1][3]. Studies including the large MELISSA trial found meloxicam as effective as comparator NSAIDs such as diclofenac and piroxicam, with fewer gastrointestinal complaints, although this relative selectivity lessens at higher doses ^[1].

In clinical use, meloxicam provides analgesic and anti-inflammatory benefit comparable to other NSAIDs for arthritic conditions ^[1][3]. Its gastrointestinal tolerability appears somewhat better than that of non-selective agents, but it is not free of risk: like all NSAIDs it can cause stomach irritation, ulcers, and bleeding, along with kidney effects and, as a class, an increased risk of cardiovascular events such as heart attack and stroke ^[2]. These class risks mean it is generally used at the lowest effective dose for the shortest necessary time ^[2].

Meloxicam is a prescription medicine in most countries, available as a low-cost generic and under brand names including Mobic, with an intravenous form marketed for acute pain ^[2]. It is also widely used in veterinary medicine. As an established NSAID it carries the standard cautions of the class, including warnings about gastrointestinal bleeding and cardiovascular risk, and it is used carefully in older adults and in people with kidney, heart, or ulcer disease ^[2].

Meloxicam is prescription only and carries the class risks of NSAIDs. It can upset the stomach and, more seriously, cause ulcers or gastrointestinal bleeding, especially with alcohol, older age, or blood thinners. It can strain the kidneys, particularly when someone is dehydrated or also taking ACE inhibitors, ARBs, or diuretics, and it can raise blood pressure and cause fluid retention. Long-term or high-dose use increases the risk of heart attack and stroke. It should be avoided in the third trimester of pregnancy and in severe heart failure, and the lowest effective dose for the shortest time is the goal.

Meloxicam interacts with lithium and requires periodic monitoring of serum lithium levels; NSAIDs are known to inhibit prostaglandin-mediated renal perfusion, potentially affecting glomerular filtration of lithium ^[6]. Lithium dose reduction is often necessary when combined with meloxicam. Meloxicam also increases blood pressure and reduces antihypertensive efficacy of ACE inhibitors and diuretics through shared renal and vascular mechanisms, though this class effect is documented less rigorously for meloxicam alone than for older NSAIDs. Pairings rarely if ever studied include meloxicam with triple-therapy regimens (NSAIDs plus ACE inhibitors plus diuretics), with selective serotonin reuptake inhibitors above standard doses (increased GI bleeding risk), and with warfarin at high intensity (additive anticoagulant effects and GI toxicity).

Checking a whole stack? Run it through interactions + stacks.

Meloxicam was developed by the German pharmaceutical company Boehringer Ingelheim as a member of the oxicam, or enolic acid, class of nonsteroidal anti-inflammatory drugs. It was introduced in Europe in the mid-1990s and gained United States Food and Drug Administration approval around 2000 under the brand name Mobic, arriving as interest in cyclooxygenase selectivity was reshaping the NSAID field. Its design gave it a preference for the inflammation-associated COX-2 enzyme over the housekeeping COX-1, a bias most pronounced at lower doses, which was expected to improve stomach tolerability relative to older, non-selective agents.

Clinical trials in osteoarthritis found it as effective as established NSAIDs such as piroxicam, diclofenac, and naproxen, while showing fewer gastrointestinal symptoms and complications in meta-analysis. It became a widely prescribed treatment for osteoarthritis and rheumatoid arthritis, and a lower-dose formulation, Vivlodex, was later introduced. Today meloxicam is a common, inexpensive generic anti-inflammatory.

Meloxicam holds a favorable reputation as a convenient, once-daily anti-inflammatory that balances effectiveness against arthritis pain with a somewhat gentler gastrointestinal profile than older NSAIDs. Much of its appeal comes from its COX-2 preference at therapeutic doses, which aims to preserve the enzyme's anti-inflammatory suppression while sparing more of the protective COX-1 in the stomach lining; clinical experience in osteoarthritis and rheumatoid arthritis has borne out this practical advantage.

A systematic review of its cardiovascular and renal safety was reassuring relative to several other NSAIDs, finding only a low, mainly vascular increase in risk and no meaningful rise in heart or kidney events. It is fair to stress that meloxicam still belongs to the NSAID family, so its selectivity fades at higher doses and it shares the class cautions around cardiovascular, kidney, and gastrointestinal effects; used at the lowest effective dose it remains a trusted choice for chronic joint pain.